Biological Features of CD5+ CD19+ B1 Cell and Natural IgM (VH4-34) in Chronic Lymphocytic Leukemia vs. Multiple

Shaghayegh Pezeshki1, Mir Hadi Jazayeri2, Bahram Chahardouli3

  • 1Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. shaghayegh.pezeshki@yahoo.com.

Insights

Chronic lymphocytic leukemia (CLL) involves increased CD5+ B cells, while multiple sclerosis (MS) shows a decrease. Researchers propose using natural antibodies from CLL patients to treat MS.

Area of Science:

  • Immunology
  • Hematology
  • Neurology

Background:

  • Chronic lymphocytic leukemia (CLL) is characterized by the clonal expansion of mature CD5+ B cells, often referred to as B1-CLL.
  • B1 cells possess anti-inflammatory properties, including natural IgM (nIgM) production and modulation of cytokines like TGFβ, crucial for tissue homeostasis.

Purpose of the Study:

  • To investigate B cell immunophenotypes and natural IgM (nIgM) levels in patients with CLL and multiple sclerosis (MS) compared to healthy controls.
  • To explore a novel therapeutic strategy for MS by leveraging the unique antibody profile of CLL patients.

Main Methods:

  • Flow cytometry was employed to immunophenotype B cells and their subpopulations in peripheral blood from CLL, MS, and control groups.
  • Real-time RT-PCR was used to quantify the VH4-34 gene copy number, a marker associated with natural IgM production.

Main Results:

  • CLL patients exhibited significantly higher proportions of CD5+ B lymphocytes compared to controls.
  • MS patients showed a significantly lower proportion of CD5+ B cells than controls.
  • CLL patients had significantly elevated VH4-34 gene copy numbers, whereas MS patients had significantly reduced levels compared to controls.

Conclusions:

  • The distinct B cell profiles and natural antibody levels in CLL and MS suggest a potential therapeutic avenue.
  • A novel treatment approach for MS is proposed, involving the extraction and administration of natural antibodies from CLL patients' sera.

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
2.5K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
3.5K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.2K